1. Scrip

Quick Acting Antibiotic Lends Promise To Destiny's Future

 
• By Sukaina Virji

Destiny Pharma's US NIAID-funded clinical study yields positive results for the novel quick-acting antibacterial exeporfinium chloride.

Destiny Pharma of the UK is developing XF-73 (exeporfinium chloride), an antibiotic for the prevention of post-surgical Staphylococcal infection, a new indication. The FDA granted the product Qualified Infectious Disease Product (QIDP) status last November. Earlier this year, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, sponsored and funded a Phase I/IIa trial to study Staphylococcus aureus decolonization (i.e. the clearance of the bacteria from the nostrils of carriers). (Also see "'Rapid Kill' Antibiotic Awaits US Data For Blanket Decolonization Prior To Surgery " - Scrip, 3 March, 2016.)

In the US trial, XF-73 was shown to be safe and demonstrated a significant anti-staphylococcal effect after just 1 day...

More from R&D

More from Scrip

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.